Ekici Kemal, Ozseker Naciye, Mayadagli Alpaslan, Erdogan Kocak Mihriban, Olmezoglu Ali
Inonu University School of Medicine, Turgut Ozal Medical Center, Radiation Oncology, Malatya, Turkey.
J BUON. 2014 Oct-Dec;19(4):1029-34.
To evaluate the efficacy and toxicity of CyberKnife stereotactic radiotherapy (SRT) for recurrent glial tumors previously treated with high-dose radiotherapy.
CyberKnife SRT was performed in 37 patients with recurrent glial tumors who presented to our hospital between January 2007 and March 2012. The patients were subjected to a dose ranging from 20 to 28 Gy using the CyberKnife system with an average of two fractions. The median follow-up duration after SRT was 14 months (range 1.8-57).
The median survival time of the patients after recurrence was 22.3 months (95% confidence interval/95% Cl 12.5-32). The median survival times of the high- and low-grade patients were 29 and 19 months, respectively. No significant toxicity due to radiation was noticed during the follow-up period. No factor influencing mortality was found in either the univariate or multivariate analysis.
SRT using CyberKnife is an effective and safe treatment choice for recurrent glial tumors. SRT achieves a more favorable outcome in the treatment of recurrent tumors, particularly in high-grade ones.
评估射波刀立体定向放射治疗（SRT）对先前接受过高剂量放疗的复发性胶质肿瘤的疗效和毒性。
2007年1月至2012年3月期间，我院对37例复发性胶质肿瘤患者实施了射波刀SRT。使用射波刀系统给予患者20至28 Gy的剂量，平均分为两部分。SRT后的中位随访时间为14个月（范围1.8 - 57个月）。
复发后患者的中位生存时间为22.3个月（95%置信区间/95% Cl 12.5 - 32）。高级别和低级别患者的中位生存时间分别为29个月和19个月。随访期间未发现明显的放射性毒性。单因素或多因素分析均未发现影响死亡率的因素。
使用射波刀的SRT是复发性胶质肿瘤有效且安全的治疗选择。SRT在复发性肿瘤治疗中取得了更有利的结果，尤其是在高级别肿瘤中。
Zotero 插件